Loading...

bluebird bio

DB:BLE
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BLE
DB
$8B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • bluebird bio has significant price volatility in the past 3 months.
BLE Share Price and Events
7 Day Returns
-6.4%
DB:BLE
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
-6.1%
DB:BLE
-7.9%
DE Biotechs
-7.2%
DE Market
BLE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
bluebird bio (BLE) -6.4% -4.9% 19.8% -6.1% 217% 778.8%
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • BLE outperformed the Biotechs industry which returned -7.9% over the past year.
  • BLE outperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
BLE
Industry
5yr Volatility vs Market
Related Companies

BLE Value

 Is bluebird bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of bluebird bio to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for bluebird bio.

DB:BLE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 18 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:BLE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (2.02%))
1.321
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.32
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.321 * 5.96%)
8.1%

Discounted Cash Flow Calculation for DB:BLE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for bluebird bio is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:BLE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.1%)
2019 -571.75 Analyst x5 -528.90
2020 -524.37 Analyst x5 -448.71
2021 -194.33 Analyst x4 -153.83
2022 617.20 Analyst x2 451.95
2023 474.11 Analyst x3 321.15
2024 387.34 Est @ -18.3% 242.71
2025 337.98 Est @ -12.74% 195.91
2026 308.07 Est @ -8.85% 165.19
2027 289.19 Est @ -6.13% 143.45
2028 276.99 Est @ -4.22% 127.10
Present value of next 10 years cash flows $516.03
DB:BLE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $276.99 × (1 + 0.23%) ÷ (8.1% – 0.23%)
$3,525.86
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,525.86 ÷ (1 + 8.1%)10
$1,617.85
DB:BLE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $516.03 + $1,617.85
$2,133.87
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,133.87 / 54.95
$38.83
DB:BLE Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:BLE represents 0.93981x of NasdaqGS:BLUE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.93981x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 38.83 x 0.93981
€36.49
Value per share (EUR) From above. €36.49
Current discount Discount to share price of €131.00
= -1 x (€131.00 - €36.49) / €36.49
-259%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of bluebird bio is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for bluebird bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are bluebird bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BLE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-10.68
NasdaqGS:BLUE Share Price ** NasdaqGS (2019-04-17) in USD $139.39
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of bluebird bio.

DB:BLE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BLUE Share Price ÷ EPS (both in USD)

= 139.39 ÷ -10.68

-13.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • bluebird bio is loss making, we can't compare its value to the Europe Biotechs industry average.
  • bluebird bio is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does bluebird bio's expected growth come at a high price?
Raw Data
DB:BLE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 18 Analysts
31.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for bluebird bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on bluebird bio's assets?
Raw Data
DB:BLE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $34.44
NasdaqGS:BLUE Share Price * NasdaqGS (2019-04-17) in USD $139.39
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:BLE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BLUE Share Price ÷ Book Value per Share (both in USD)

= 139.39 ÷ 34.44

4.05x

* Primary Listing of bluebird bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • bluebird bio is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess bluebird bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. bluebird bio has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BLE Future Performance

 How is bluebird bio expected to perform in the next 1 to 3 years based on estimates from 18 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
31.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is bluebird bio expected to grow at an attractive rate?
  • bluebird bio's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • bluebird bio's earnings growth is expected to exceed the Germany market average.
  • bluebird bio's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BLE Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BLE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 18 Analysts 31.4%
DB:BLE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 18 Analysts 48.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BLE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BLE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,376 512 744 11
2022-12-31 823 203 -153 12
2021-12-31 458 -116 -447 14
2020-12-31 198 -435 -617 16
2019-12-31 64 -507 -651 18
DB:BLE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 55 -413 -556
2018-09-30 40 -379 -524
2018-06-30 36 -361 -457
2018-03-31 45 -314 -382
2017-12-31 35 -281 -336
2017-09-30 33 -254 -290
2017-06-30 27 -237 -288
2017-03-31 11 -228 -276
2016-12-31 6 -190 -264
2016-09-30 6 -154 -239
2016-06-30 6 -143 -205
2016-03-31 9 -111 -198

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • bluebird bio's earnings are expected to grow significantly at over 20% yearly.
  • bluebird bio's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BLE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below

All data from bluebird bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BLE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 9.48 17.45 1.63 7.00
2022-12-31 -2.42 6.19 -9.67 13.00
2021-12-31 -7.61 -3.41 -12.32 14.00
2020-12-31 -10.55 -5.13 -14.00 19.00
2019-12-31 -11.86 -9.19 -13.48 21.00
DB:BLE Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -10.68
2018-09-30 -10.48
2018-06-30 -9.51
2018-03-31 -8.34
2017-12-31 -7.71
2017-09-30 -7.00
2017-06-30 -7.33
2017-03-31 -7.21
2016-12-31 -7.07
2016-09-30 -6.48
2016-06-30 -5.59
2016-03-31 -5.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if bluebird bio will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess bluebird bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
bluebird bio has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BLE Past Performance

  How has bluebird bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare bluebird bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • bluebird bio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare bluebird bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare bluebird bio's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
bluebird bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from bluebird bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BLE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 54.58 -555.63 174.13
2018-09-30 39.50 -523.83 149.71
2018-06-30 35.69 -457.15 128.16
2018-03-31 44.55 -382.06 108.19
2017-12-31 35.43 -335.64 93.55
2017-09-30 32.81 -289.78 80.64
2017-06-30 26.65 -288.00 72.28
2017-03-31 11.49 -275.95 69.45
2016-12-31 6.16 -263.51 65.12
2016-09-30 6.08 -239.42 63.39
2016-06-30 5.85 -205.32 62.47
2016-03-31 9.23 -198.27 54.83
2015-12-31 14.08 -166.78 46.21
2015-09-30 18.99 -139.05 36.07
2015-06-30 24.04 -113.16 29.01
2015-03-31 25.43 -62.89 24.02
2014-12-31 25.42 -48.71 23.23
2014-09-30 25.37 -37.25 22.61
2014-06-30 25.39 -26.33 19.80
2014-03-31 25.39 -29.39 17.34
2013-12-31 20.18 -25.32 14.13
2013-09-30 13.93 -20.96 11.99
2013-06-30 7.63 -14.54 9.76
2013-03-31 1.38 -3.80 7.81
2012-12-31 0.34 -3.61 6.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if bluebird bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if bluebird bio has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if bluebird bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess bluebird bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
bluebird bio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BLE Health

 How is bluebird bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up bluebird bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • bluebird bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • bluebird bio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of bluebird bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 9.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from bluebird bio Company Filings, last reported 3 months ago.

DB:BLE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,885.07 154.74 1,385.30
2018-09-30 2,000.79 155.03 1,695.30
2018-06-30 1,457.53 155.32 1,076.96
2018-03-31 1,570.20 155.59 1,121.58
2017-12-31 1,623.43 155.80 1,290.11
2017-09-30 1,141.32 155.06 728.77
2017-06-30 1,200.02 153.96 1,095.43
2017-03-31 815.38 147.56 634.07
2016-12-31 869.44 120.14 704.38
2016-09-30 694.51 99.99 600.96
2016-06-30 759.29 86.63 575.80
2016-03-31 806.51 74.41 553.10
2015-12-31 850.50 61.90 517.95
2015-09-30 889.01 43.78 707.46
2015-06-30 918.97 0.00 810.51
2015-03-31 474.50 0.00 334.88
2014-12-31 491.26 0.00 473.56
2014-09-30 261.89 0.00 215.37
2014-06-30 165.76 0.00 175.71
2014-03-31 144.17 0.00 192.50
2013-12-31 151.67 0.00 206.28
2013-09-30 157.70 0.00 216.79
2013-06-30 161.27 0.00 228.85
2013-03-31 58.50 0.00 131.84
2012-12-31 64.09 0.00 67.01
  • bluebird bio's level of debt (8.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 8.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • bluebird bio has sufficient cash runway for more than 3 years based on current free cash flow.
  • bluebird bio has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 43.8% each year.
X
Financial health checks
We assess bluebird bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. bluebird bio has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BLE Dividends

 What is bluebird bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from bluebird bio dividends. Estimated to be 0% next year.
If you bought €2,000 of bluebird bio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate bluebird bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate bluebird bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BLE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BLE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as bluebird bio has not reported any payouts.
  • Unable to verify if bluebird bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of bluebird bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as bluebird bio has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of bluebird bio's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess bluebird bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can bluebird bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. bluebird bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BLE Management

 What is the CEO of bluebird bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nick Leschly
COMPENSATION $8,762,290
AGE 45
TENURE AS CEO 8.6 years
CEO Bio

Mr. Nick Leschly has been the Chief Executive Officer and President at bluebird bio, Inc. (alternate name Genetix Pharmaceuticals Inc.) since September 2010. Mr. Leschly served as Interim President at bluebird bio, Inc. until September 2010. He was a Partner at Third Rock Ventures, LLC since 2007. He served as the Chief Business Officer of Agios Pharmaceuticals, Inc. Prior to joining Third Rock, he was the Product and Alliance Leader for Millennium Pharmaceuticals, Inc., and was the Product Leader for VELCADE™, managing a S100M+ global development plan. Mr. Leschly founded and served as the Chief Financial Officer of MedXtend Corporation. He joined Third Rock Ventures in 2007 as a Founding Member and played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals (AGIO), Inc. as well as identifying and evaluating new investments. He worked at Accenture Consulting, where he focused on the pharmaceutical industry. Mr. Leschly has been a Director of bluebird bio, Inc. since March 2010. He has been an Independent Director at Synlogic, Inc. since March 2016. Mr. Leschly served as Director of Edimer Pharmaceuticals Inc. He is the Founder and Chairman of The CAVU foundation. He is a Board Member of the Biotechnology Innovation Organization (BIO). Mr. Leschly holds a BS in Molecular Biology from Princeton University and an MBA from Wharton Business School.

CEO Compensation
  • Nick's compensation has increased whilst company is loss making.
  • Nick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the bluebird bio management team in years:

2.1
Average Tenure
46.5
Average Age
  • The tenure for the bluebird bio management team is about average.
Management Team

Nick Leschly

TITLE
President
COMPENSATION
$9M
AGE
45
TENURE
8.6 yrs

Jason Cole

TITLE
Chief Operating & Legal Officer and Secretary
COMPENSATION
$3M
AGE
45
TENURE
0.2 yrs

Philip Gregory

TITLE
Chief Scientific Officer
COMPENSATION
$3M
AGE
47
TENURE
3.8 yrs

Jeff Walsh

TITLE
Chief Strategy Officer
COMPENSATION
$5M
AGE
52
TENURE
3.1 yrs

Dave Davidson

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
54
TENURE
7.2 yrs

Chip Baird

TITLE
Chief Financial Officer
AGE
46
TENURE
0.2 yrs

Kory Wentworth

TITLE
VP of Finance
AGE
39
TENURE
1.3 yrs

Derek Adams

TITLE
Chief Technology & Manufacturing Officer
TENURE
2.1 yrs

Stephanie Fagan

TITLE
Senior Vice President of Corporate Communications
TENURE
1.3 yrs

Joanne Smith-Farrell

TITLE
Senior Vice President of Corporate Development & Strategy
AGE
48
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the bluebird bio board of directors in years:

8.1
Average Tenure
60
Average Age
  • The tenure for the bluebird bio board of directors is about average.
Board of Directors

Dan Lynch

TITLE
Chairman
COMPENSATION
$668K
AGE
60
TENURE
7.9 yrs

Nick Leschly

TITLE
President
COMPENSATION
$9M
AGE
45
TENURE
9.1 yrs

Philippe Leboulch

TITLE
Co-Chair of Scientific Advisory Board

David Schenkein

TITLE
Director
COMPENSATION
$458K
AGE
61
TENURE
6 yrs

Mark Vachon

TITLE
Director
COMPENSATION
$466K
AGE
59
TENURE
4.8 yrs

Mitch Finer

TITLE
Member of Scientific Advisory Board
COMPENSATION
$2M
AGE
59
TENURE
3.8 yrs

Phil Reilly

TITLE
Member of Scientific Advisory Board
AGE
70
TENURE
8.1 yrs

Malcolm Brenner

TITLE
Member of Scientific Advisory Board
TENURE
8.1 yrs

Christof von Kalle

TITLE
Member of Scientific Advisory Board
TENURE
8.1 yrs

Steve Goff

TITLE
Member of Scientific Advisory Board
AGE
66
TENURE
8.1 yrs
Who owns this company?
Recent Insider Trading
  • bluebird bio insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Mar 19 Sell Kory Wentworth Individual 28. Feb 19 28. Feb 19 -51 €133.22 €-6,794
09. Jan 19 Sell Jason Cole Individual 07. Jan 19 07. Jan 19 -1,416 €99.69 €-140,333
09. Jan 19 Sell Jeffrey Walsh Individual 07. Jan 19 07. Jan 19 -3,012 €99.69 €-298,499
09. Jan 19 Sell Nick Leschly Individual 07. Jan 19 07. Jan 19 -7,374 €99.69 €-730,790
09. Jan 19 Sell David Davidson Individual 07. Jan 19 07. Jan 19 -2,664 €99.69 €-264,014
09. Jan 19 Sell Alison Finger Individual 07. Jan 19 07. Jan 19 -643 €99.68 €-63,722
09. Jan 19 Sell Alison Finger Individual 03. Jan 19 03. Jan 19 -476 €87.95 €-41,444
21. Dec 18 Sell Kory Wentworth Individual 19. Dec 18 19. Dec 18 -388 €90.19 €-34,993
06. Dec 18 Sell Susanna High Individual 03. Dec 18 03. Dec 18 -1,890 €100.25 €-189,470
22. Aug 18 Sell Alison Finger Individual 20. Aug 18 20. Aug 18 -259 €138.24 €-35,798
13. Jul 18 Sell Philip Gregory Individual 18. Jun 18 18. Jun 18 -3,901 €156.13 €-599,168
X
Management checks
We assess bluebird bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. bluebird bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BLE News

Simply Wall St News

BLE Company Info

Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company’s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Details
Name: bluebird bio, Inc.
BLE
Exchange: DB
Founded: 1992
$6,778,019,473
54,951,177
Website: http://www.bluebirdbio.com
Address: bluebird bio, Inc.
60 Binney Street,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BLUE Common Shares Nasdaq Global Select US USD 19. Jun 2013
DB BLE Common Shares Deutsche Boerse AG DE EUR 19. Jun 2013
LSE 0HOH Common Shares London Stock Exchange GB USD 19. Jun 2013
Number of employees
Current staff
Staff numbers
764
bluebird bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 22:52
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/02/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.